Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Stuart Elborn

Showing results (181-190 of 290) with videos related to

Pageof 29
Sort By:
Chest|July 11, 2016
Lung Clearance Index in Adults and Children With Cystic FibrosisKatherine O'Neill, Michael M Tunney, Elinor Johnston, et al.
The Journal of Antimicrobial Chemotherapy|September 17, 2018
Activity of hypothiocyanite and lactoferrin (ALX-009) against respiratory cystic fibrosis pathogens in sputumMichael M Tunney, Joanna E Payne, Stephanie J McGrath, et al.
The European Respiratory Journal|January 27, 2018
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasisAnthony De Soyza, Timothy Aksamit, Tiemo-Joerg Bandel, et al.
The European Respiratory Journal|January 27, 2018
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasisTimothy Aksamit, Anthony De Soyza, Tiemo-Joerg Bandel, et al.
Respiratory Medicine|January 8, 2022
Bronchiectasis and inhaled tobramycin: A literature reviewJ Stuart Elborn, Francesco Blasi, Charles S Haworth, et al.
Lung|September 16, 2015
Lack of Association Between Haptoglobin Phenotype and Cystic Fibrosis OutcomesMichal Shteinberg, Joseph Rivlin, Michal Gur, et al.
Plos One|May 21, 2015
Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosisKatherine O'Neill, Judy M Bradley, Elinor Johnston, et al.
International Journal of Antimicrobial Agents|January 18, 2016
Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiotaLaura J Sherrard, Stef J McGrath, Leanne McIlreavey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2014
European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosisMartin Stern, Dominique Pougheon Bertrand, Elisabetta Bignamini, et al.
Pulmonary Pharmacology & Therapeutics|August 28, 2014
Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosisAshish Sharma, David E Geller, Petra Moroni-Zentgraf, et al.
Pageof 29

Showing results (181-190 of 290) with videos related to

Sort By:
Pageof 29
Chest|July 11, 2016
Lung Clearance Index in Adults and Children With Cystic FibrosisKatherine O'Neill, Michael M Tunney, Elinor Johnston, et al.
The Journal of Antimicrobial Chemotherapy|September 17, 2018
Activity of hypothiocyanite and lactoferrin (ALX-009) against respiratory cystic fibrosis pathogens in sputumMichael M Tunney, Joanna E Payne, Stephanie J McGrath, et al.
The European Respiratory Journal|January 27, 2018
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasisAnthony De Soyza, Timothy Aksamit, Tiemo-Joerg Bandel, et al.
The European Respiratory Journal|January 27, 2018
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasisTimothy Aksamit, Anthony De Soyza, Tiemo-Joerg Bandel, et al.
Respiratory Medicine|January 8, 2022
Bronchiectasis and inhaled tobramycin: A literature reviewJ Stuart Elborn, Francesco Blasi, Charles S Haworth, et al.
Lung|September 16, 2015
Lack of Association Between Haptoglobin Phenotype and Cystic Fibrosis OutcomesMichal Shteinberg, Joseph Rivlin, Michal Gur, et al.
Plos One|May 21, 2015
Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosisKatherine O'Neill, Judy M Bradley, Elinor Johnston, et al.
International Journal of Antimicrobial Agents|January 18, 2016
Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiotaLaura J Sherrard, Stef J McGrath, Leanne McIlreavey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2014
European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosisMartin Stern, Dominique Pougheon Bertrand, Elisabetta Bignamini, et al.
Pulmonary Pharmacology & Therapeutics|August 28, 2014
Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosisAshish Sharma, David E Geller, Petra Moroni-Zentgraf, et al.
Pageof 29